港股異動 | 方達控股放量大漲逾10% 機構稱實行 “兩國一制”確保專業能力
格隆匯2月17日丨方達控股(1521.HK)今日放量大漲,現升10.28%,報5.04港元,暫成交1.3億港元,最新總市值101.6億港元。

公司是一家為醫藥公司提供貫穿整個藥物發現和開發過程的一體化、科學驅動的研究、分析和開發服務的合同研究機構。近期受疫情影響,醫藥生物科技股走勢較強。
日前,輝立證券報告稱,公司業務覆蓋中美兩地,“兩國一制”確保專業能力,給予“增持”評級。2018年全球製藥合同研究機構市場規模為552億美元,預計2023年將增至914億美元,複合年增率為10.6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.